VIP FAQ: common questions answered
A blood-vessel and immune signal studied in lung disease; nasal CIRS benefits remain unproven.
Also called: Vasoactive intestinal peptide, Vasoactive intestinal polypeptide, Aviptadil, RLF-100, Zyesami.
Immune peptides · VPAC1 and VPAC2 receptor agonist.
- Is VIP FDA-approved? No FDA-approved product found. PCAC voted against 503A listing on November 3, 2016; FDA proposed exclusion in 2019. VIP remains on the May 2026 Category 1 interim list.
- How do people take it? Nasal spray, four times daily. Source: reported by users, not an established dose.
- What's the difference between VIP and KPV? VIP: a blood-vessel and immune signal studied in lung disease; nasal CIRS benefits remain unproven. KPV: an alpha-MSH fragment studied for gut inflammation in animals, with no human dosing trial. Why people pair them: a forum user reports overlapping low-dose VIP while finishing KPV. No human combination trial was found.
- Can I take it with KPV? A forum user reports overlapping low-dose VIP while finishing KPV. No human combination trial was found. Adds another unapproved exposure; no validated timing or interaction data. Source: reported by users. Ask a doctor before combining anything.
- Is it banned in sport? It is unclear (WADA 2026). VIP is not named. S0 concerns substances lacking any governmental human-use approval; licensed VIP combinations complicate that inference. No VIP-specific ruling was found.
- How long does a mixed vial last? Home-mixed VIP has no verified stability or sterility period. The 2017 study’s refrigerated 60-day limit applied to its specific nasal formulation.
Related to VIP
- Thymosin alpha-1: An immune-signaling peptide with overseas approvals and mixed trial results.
- KPV: An alpha-MSH fragment studied for gut inflammation in animals, with no human dosing trial.
Sources
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- EU/3/26/3200 - orphan designation for treatment of acute respiratory distress syndrome (ARDS), 2026
- Pyrogen and Endotoxins Testing: Questions and Answers, FDA · 2026
- The Prohibited List, World Anti-Doping Agency · World Anti-Doping Agency · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Think twice before injecting peptides bought online: unauthorized products can seriously harm you, Health Canada · Health Canada · 2026
- Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act, 2025
- Amendments to the List of Bulk Drug Substances That Can Be Used to Compound Drug Products in Accordance With Section 503A of the Federal Food, Drug, and Cosmetic Act, 2019
- AWMSG Secretariat Assessment Report. Aviptadil/phentolamine mesilate (Invicorp) 25 micrograms/2 mg solution for injection, 2017
- Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances, FDA · FDA · 2000
- Search Orphan Drug Designations and Approvals, FDA · FDA
- VALMISTEYHTEENVETO
- INTRAVENOUS AVIPTADIL AS ADJUNCTIVE THERAPY IN ACUTE RESPIRATORY DISTRESS SYNDROME: AN OBSERVATIONAL CASE SERIES OF SIX PATIENTS, 2026
- Aviptadil Therapy in Acute Respiratory Distress Syndrome Patients: A Systematic Review and Meta-analysis., Udupa AA et al. · Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2025
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.